68
Participants
Start Date
September 30, 2006
Primary Completion Date
July 31, 2009
Study Completion Date
December 31, 2025
Bortezomib
Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
Lenalidomide
Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
dexamethasone
Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (2)
Brigham and Women's Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Massachusetts General Hospital
OTHER
Celgene Corporation
INDUSTRY
Millennium Pharmaceuticals, Inc.
INDUSTRY
Dana-Farber Cancer Institute
OTHER